In the suddenly crowded field vying for the breakfast market, smoothie pourer Jamba Juice is getting up early to stake its claim. Jamba
New juice blends, yogurt blends, and granola-topped dairy drinks will aim to hook hungry morning commuters. Not everything on the regular Jamba menu is wholesomely good for you, but the chain certainly offers healthier alternatives than the fried fare at fast-food joints or doughnut shops like Krispy Kreme
Unlike the seasoned morning vets at standalone Burger King
The market for the breakfast dollar is also getting more competitive. Wendy's
The timing of the breakfast push couldn't come at a better time for the company, though. Jamba just completed its seasonally strongest quarter with lackluster results. Demand for Jamba's smoothies tend to wane as the summer heat fizzles, so now would be a good time to see if it can do something to smoothen out the seasonality while improving sluggish comps.
I guess that's why they call them smoothies? Bad joke, I know, but with Jamba's share price dipping well into the single digits, the breakfast catalyst -- even if it seems as nutty as granola -- is as good a reason as any to get excited about waking up to the whir of institutional blenders in the morning.
Former odes to Jamba and other earthy drinks:
Starbucks has been recommended to Motley Fool Stock Advisor newsletter subscribers. Forget about functional breakfast smoothies for a moment. Feed your head with a free 30-day trial subscription to any of the Fool's newsletters.
Longtime Fool contributor Rick Munarriz is about a 10-minute walk from a Jamba Juice, and he makes that trek often. He does own shares in Jamba. He is part of the Rule Breakers newsletter research team, seeking out tomorrow's ultimate growth stocks a day early. The Fool has a disclosure policy, and it comes with a free immunity boost.
More from The Motley Fool
Why the Apple Inc. iPhone X Isn't Doing as Well as Hoped in China
The answer might surprise you.
3 Signs You're Better Off Delaying Retirement
If you're coping with any of the issues below, then retiring now is probably a bad idea.
Better Buy: Gilead Sciences, Inc. vs. Pfizer Inc.
Which stock wins in a head-to-head match-up between the big biotech and the big pharma company?